Rheumatology

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

MEDICAL FRONTIERS - Annual Meeting of the American College of Rheumatology

Update on the Impact of IL-17A Inhibition on Disease Severity and Structural Changes in Axial Spondyloarthritis

San Diego, California / November 4-7, 2017

San Diego - Joint symptoms and structural joint damage are two targets of the treatment of axial spondyloarthritis (axSpA), which encompasses psoriatic arthritis and ankylosing spondylitis. Inhibition of interleukin-17A, a key cytokine...

PRIORITY PRESS - Annual Meeting of the American College of Rheumatology (ACR) 2015

Spondyloarthritis: Interleukin-17a Underlies its Pathophysiology

San Francisco, California / November 6-11, 2015

San Francisco - Complex interactions between immunologic mediators, including interleukin (IL)-17a, underlie the pathogenesis of spondyloarthritis (SpA), which includes psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Although the...

PRIORITY PRESS - Annual European Congress of Rheumatology (EULAR)

Patient Perspectives in the Rheumatology Clinic

Rome, Italy / June 10-13, 2015

Rome - Over the past decade the number of treatment strategies for patients with rheumatoid arthritis (RA) has increased substantially leaving rheumatologists with several options to think about when managing their patients. A recurrent...

MEDPOINT - 69th Annual Meeting of the Canadian Rheumatology Association (CRA)

Diagnosis, Assessment Tools and the Management of Gout

Whistler, BC / February 26-March 1, 2014

Whistler, BC - Gout may be perceived as an ailment or minor illness, but it can cause as much disability as rheumatoid or psoriatic arthritis, and thus deserves urgent and expert attention. New imaging and therapeutic options are emerging...

MEDICAL FRONTIERS - European Respiratory Society (ERS) Annual Congress 2013

New Treatment Options in Pulmonary Arterial Hypertension Appear to Move Treatment Goals Beyond Symptom Control

Barcelona, Spain / September 7-11, 2013

Barcelona - New data presented at the ERS 2013 from trials published just weeks before the meeting was convened, document a paradigm shift in the treatment of pulmonary hypertension. In pulmonary arterial hypertension, the benefit of a new...

PRIORITY PRESS - International Conference of the American Thoracic Society

Updates in the Treatment of Chronic Thromboembolic Pulmonary and Pulmonary Arterial Hypertension

Philadelphia, Pennsylvania / May 17-22, 2013

Philadelphia - Currently, the gold standard for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA) but when patients are deemed inoperable or when symptoms persist or recur following PEA, new medical...

MEDI-NEWS - Head-to-Head Comparisons of Biologics in Rheumatoid Arthritis: Closing the Data Gap

Based on Arthritis Rheum 2012;64(12):3850-5; Arthritis Rheum 2013:65(1):28-38; The Lancet Published online March 18, 2013.

March 2013

Over the past decade, the biologics have significantly enhanced the management of patients with rheumatoid arthritis (RA) and continue to do so with the emergence of new biologics with different modes of action. Until recently, no...

PRIORITY PRESS - 76th Annual Meeting of the American College of Rheumatology (ACR)

Protection Against Radiologic Progression in Rheumatoid Arthritis with JAK Inhibition Appears Similar to IV Biologics

Washington, DC / November 10-14, 2012

Washington, DC - Oral agents that target intracellular pathways of inflammation are showing remarkable similarities to injectable monoclonal antibodies in the control of rheumatoid arthritis (RA). Along with phase III data supporting the...

MEDICAL FRONTIERS - 2012 Annual European Congress of Rheumatology (EULAR)

Oral Biologics Gain Attention as Safety Data Catch Up with Efficacy Data in Rheumatoid Arthritis Control

Berlin, Germany / June 6-9, 2012

Berlin - The potential to target the inflammatory cascade with oral rather than injectable targeted therapies in rheumatoid arthritis (RA) remains strong, based on studies evaluating agents with different mechanisms that were presented at...

PRIORITY PRESS - 2012 Annual European Congress of Rheumatology (EULAR)

Progress in Oral Biologics for Rheumatoid Arthritis

Berlin, Germany / June 6-9, 2012

Berlin - Oral therapies for rheumatoid arthritis that target very specific molecular steps in the inflammatory pathway have reached phase III trials. The data generated from these trials indicate that the anti-inflammatory activity of...

PAGE 1 OF 7   1 2 3 4 5 6 7